EnGeneIC Announces Strategic Partnerships with Singaporean Medical Institutions
EnGeneIC, a clinical-stage biopharmaceutical company focused on advancing its proprietary targeted nanocell technology for cancer therapy, has announced strategic partnerships with Singapore Institute of Advanced Medicine Holdings (SAM) and Singapore Medical Incorporation (SMI). These partnerships will provide significant funding for EnGeneIC to progress its clinical trials in Australia and the USA and accelerate clinical development and commercialization of EnGeneIC’s technology for cancer treatment across Asia.
The Partnership Details
Under the agreement, SAM will gain exclusive rights to sell EnGeneIC Dream Vector (EDV) therapeutics in Asia while EnGeneIC will receive a majority of net profits. The two companies will also collaborate on the development of EDV-based theranostics, which combine therapeutic and diagnostic capabilities to improve cancer treatment outcomes. By integrating imaging and treatment into a single platform, EDV-based theranostics have the potential to provide precise, personalized care, enabling early detection and targeted therapy.
Crescendas Group, a Singapore-based diversified property, technology, and hospitality entity owned by prominent Singaporean businessman Mr. Lawrence Leow, provided funds for the capital expenditure requirements needed to complete the next phase of clinical tests to secure Food and Drug Administration (FDA) approval in the US.
The Significance of the Partnerships
The partnerships mark a significant milestone for EnGeneIC, expanding the company’s footprint into its Asian neighbors. Dr. Jennifer MacDiarmid, Joint CEO of EnGeneIC, said, “Our EDV technology is poised to transform cancer treatment, and together with our partners’ expertise and resources, we are well-positioned to bring EDVs to a much broader patient population.”
The partnership aligns EnGeneIC’s mission to advance medical innovation and improve patient outcomes. Dr. Shih Kien Djeng, Chairman and CEO of SAM, said, “We are excited to collaborate with EnGeneIC to bring their cutting-edge EDV-based therapeutics to Singapore and Asia. By combining our strengths, we aim to deliver revolutionary cancer treatments that offer new hope to patients throughout the region.”
About EnGeneIC
EnGeneIC is a clinical-stage biopharmaceutical company focused on advancing its proprietary EDV (EnGeneIC Dream Vector) nanocell technology for oncology and infectious disease applications. The EDV nanocell is the foundation of a first-in-class antibody nanocell drug conjugate platform for delivering a range of therapeutic payloads – drugs, siRNAs, miRNAs, adjuvants – via antibody-targeting a cancer cell’s surface, with minimal toxicity.
For cancer applications, the EDV technology enables delivery of the most potent chemotherapeutic agents, effectively overcoming drug-resistance and killing tumor cells, while simultaneously stimulating the patient’s immune system, allowing a potent antitumor response. EnGeneIC is entering Phase IIa clinical trials in Australia and the USA in patients with intractable, low survival cancers, including patients with metastatic pancreatic cancer.
About Singapore Institute of Advanced Medicine Holdings
Singapore Institute of Advanced Medicine Holdings Ltd (SAM) is a healthcare service provider in Singapore that uses advanced technology for early and accurate diagnosis and treatment of a variety of diseases and health conditions, including cancer, neurodegenerative, and cardiovascular diseases. SAM’s services include Nuclear Medicine and Theranostics, Proton Therapy, and Radiation Therapy. SAM has strategic collaborations with public and private institutions for research and clinical work.
Originally Post From https://www.biospace.com/article/releases/engeneic-and-singapore-institute-of-advanced-medicine-holdings-forge-strategic-partnership-to-revolutionise-cancer-treatment-in-asia/
Read more about this topic at
Adaptive Biotechnologies, Genentech Form Personalized …
Resilience hails $625 million in financing and a cancer …
